Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient‐Derived Tissue Laden Tissue‐Specific Bioink (Adv. Sci. 10/2025)

Drug Efficacy Testing The cover image illustrates a 3D bioprinted gastric cancer (pGC) model, developed using patient-derived tumor tissues and gastric decellularized extracellular matrix (g-dECM) bioinks. This innovative platform enables precise and efficient evaluation of chemotherapy responses. The visual highlights the seamless integration of patient biopsy-derived tissues, tissue-specific bioinks, and cutting-edge bioprinting technology, demonstrating its potential for in vitro drug sensitivity testing. More details can be found in article number 2411769 by Charles Lee, Jinah Jang, and co-workers.